Features of the use of the antibacterial drug josamycin in gynecological practice

Background. Currently, urogenital chlamydia occupies the first place in terms of prevalence among all bacterial sexually transmitted diseases. Along with chlamydia, other intracellular pathogens, mycoplasmas and ureaplasmas, are attracting increasing attention in the etiology of urogenital diseases. Inflammatory diseases of the pelvic organs cause significant damage to the health of women, contribute to the violation of reproductive function, reduce the quality of life, as well as the formation of life-threatening conditions in severe course. The issues of timely diagnosis of inflammatory diseases of the reproductive system present many difficulties, justified by the vagueness of clinical symptoms, the variety of causative agents, as well as the different course of the inflammatory process. Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis are the leading etiologic factors of inflammatory diseases of pelvic organs, up to 60% of cases of inflammatory diseases of female genital organs are the result of microbial associations of Chlamydia trachomatis, Mycoplasma genitalium. These infections are most dangerous during pregnancy. Difficulties in diagnosis lead to delayed treatment, which contributes to an increase in the number of chronic forms of diseases and unfavorable outcomes associated with a complicated course of diseases. Therapy of inflammatory diseases of the genitals requires a comprehensive approach and causes a lot of discussion, the main link of treatment is the rational selection of antibacterial therapy.

Results. This review demonstrates current data on the high efficacy and safety of the use of josamycin in the treatment of these diseases. The use of the domestic drug with active substance josamycin in the treatment of inflammatory diseases of the pelvic organs, urogenital chlamydia and mycoplasmosis, especially during pregnancy, is effective and safe, and will reduce the frequency of adverse pregnancy outcomes and infectious and inflammatory complications.

1. Khashukoeva A. Z., Agaeva M. I., Agaeva Z. A., Savchenko T. N., Lobpcheva Yu. I. Inflammatory diseases of pelvic organs: modern algorithms of diagnosis and treatment. Lechaschi Vrach. 2024. 27 (5): 12-17. (In Russ.)

2. Damkier P., Brønniche L. M. S., Korch-Frandsen J. F. B., Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol. 2019; 221 (6): 648.e1-648.e15. DOI: 10.1016/j.ajog.2019.06.050. PubMed.

3. Tubiana S., Sibiude J., Herlemont P., Drouin J., Picone O., Duval X., et al. Trends in anti-infective use during pregnancy in France between 2010 and 2019: a nationwide population-based study. Br J Clin Pharmacol. 2023; 89 (5): 1629-1639. DOI: 10.1111/bcp.15638. PubMed.

4. Ushkalova E. A. The place of josamycin in the treatment of urogenital infections caused by intracellular pathogens. Farmateka. 2006. 4 (119): 5-6. (In Russ.)

5. Mansour O., Russo R. G., Straub L., Bateman B. T., Gray K. J., Huybrechts K. F., et al. Prescription medication use during pregnancy in the United States from 2011 to 2020: trends and safety evidence. Am J Obstet Gynecol. 2024; 231 (2): 250.e1–250.e16. DOI: 10.1016/j.ajog.2023.12.020. PMC – PubMed.

6. Bookstaver P. B., Bland C. M., Griffin B., Stover K. R., Eiland L. S., McLaughlin M. A. Review of Antibiotic Use in Pregnancy. Pharmacotherapy. 2015. Р. 1052-1062. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26598097. PubMed.

7. Loran O. B., Sinyakova L. A., Kosova I. V. Uncomplicated urinary tract infections: the problem of choosing a rational antimicrobial therapy. Farmateka. 2004. № 11. (In Russ.)

8. Antonucci R., Cuzzolin L., Locci C., Dessole F., Capobianco G. Use of azithromycin in pregnancy: more doubts than Certainties. Clin Drug Investig. 2022; 42 (11): 921-935. DOI: 10.1007/s40261-022-01203-0. PMC – PubMed.

9. Zimmerman M. S., Smith A. G. C., Sable C. A., Echko M. M., Wilner L. B., Olsen H. E., et al. Global, regional, and national burden of congenital heart disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Child Adolesc Health. 2020; 4 (3): 185-200. DOI: 10.1016/S23524642(19)30402-X. PMC – PubMed.

10. Майоров М. В. Урогенитальный хламидиоз в амбулаторной гинекологии. Провизор. 2004; 10. Mayorov M. V. Urogenital chlamydia in outpatient gynecology. Provizor. 2004; 10. (In Russ.)

11. Fan H., Gilbert R., O’Callaghan F., Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ. 2020; 368: m331. DOI: 10.1136/bmj.m331. PMC – PubMed.

12. Andersson N. W., Olsen R. H., Andersen J. T. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study. BMJ. 2021; 372: n107. DOI: 10.1136/bmj.n107. PMC – PubMed.

13. Muanda F., Sheehy O., Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. Br J ClinPharmacol. 2017; 83 (12): 2557-2571. PMC – PubMed.

14. Bérard A., Sheehy O., Zhao J.-P., Nordeng H. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. Pharmacoepidemiol Drug Saf. 2015; 24 (12): 1241-1248. DOI: 10.1002/pds.3900. PubMed.

15. Tyutyunnik V. L., Mikhailova O. I., Medzhidova M. K. Nonspecific vaginitis: etiology, pathogenesis, clinic, diagnosis, modern principles of treatment. Akusherstvo i ginekologiya. 2011; 7-2: 92-96. (In Russ.)

16. Vasilev M. M., Navolotskaya T. I., Smirnova A. A., Frigo N. V., Rotanov S. V., Sidorovich S. Yu. The use of josamycin (vilprafen) in women with chlamydial infection of the lower and upper parts of the urogenital tract. Vestnik dermatologii i venerologii. 2005; 3: 78-80. (In Russ.)

17. Mirskaya Yu. I., Rudakova E. B., Shakira I. A., Tsygankova O. Yu. Role of cervicitis in obstetric and gynecologic pathology. Lechaschi Vrach. 2009; 10: 63-66. (In Russ.)

18. Keskin-Arslan E., Erol H., Uysal N., Karadas B., Temiz T., Kaplan Y. C. Pregnancy outcomes following maternal macrolide use: a systematic review and meta-analysis. Reprod Toxicol. 2023; 115: 124-146. DOI: 10.1016/j.reprotox.2022.12.003. PubMed.

19. Blotière P.-O., Weill A., Dalichampt M., Billionnet C., Mezzarobba M., Raguideau F., et al. Development of an algorithm to identify pregnancy episodes and related outcomes in health care claims databases: an application to antiepileptic drug use in 4.9 million pregnant women in France. Pharmacoepidemiol Drug Saf. 2018; 27 (7): 763-770. DOI 10.1002/pds.4556. PMC – PubMed.

20. Blotière P.-O., Raguideau F., Weill A., Elefant E., Perthus I., Goulet V., et al. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology. 2019; 93 (2): 167-80. DOI: 10.1212/WNL.0000000000007696. PMC – PubMed.

21. Lassalle M., Zureik M., Dray-Spira R. Proton pump inhibitor use and risk of serious infections in young children. JAMA Pediatr. 2023; 177 (10): 1028-1038. DOI 10.1001/jamapediatrics.2023.2900. PMC – PubMed.

22. Minkevich K. V., Zaitseva A. A. Application of new generation macrolide for treatment of genital chlamydia in women. Akusherstvo i ginekologiya. 2001; 8: 14-18. (In Russ.)

23. EUROCAT Guide 1.4 and Reference Documents. European Surveillance of Congenital Anomalies; 2018. Available from: https://eu-rd-platform.jrc.ec.europa.eu/sites/default/files/Full_Guide_1.

24. Desai R. J., Rothman K. J., Bateman B. T., Hernandez-Diaz S., Huybrechts K. F. A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent. Epidemiology. 2017. Р. 249-257. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27922533. PMC – PubMed.

25. Tatochenko V. К. Josamycin in pediatric practice. Pediatriya. 2011; 5 (90): 124-128. (In Russ.)

26. Savicheva A.M., Shipitsina E. V., Selimyan N. K. Vilprafen (josamycin) in the therapy of urogenital chlamydial infection. Vestnik dermatologii i venerologii. 2004; 2: 62-65. (In Russ.)

27. Kisina V. I., Kovalyk V. P., Kolieva G. L. Criteria for the choice of recommended and alternative methods of treatment of urogenital infections. Trudnyi patsient. 2005; 2. (In Russ.)

28. Malova I. O. Vilprafen (jozamycin) in the treatment of chlamydial and mixed infections of the urogenital tract in young girls. Rossiiskii vestnik perinatologii i pediatrii. 2001; 4. (In Russ.)

29. .Instructions for the medical use of the Dzhozafen drug (In Russ.)

30. A prospective, open-label, randomized, full replicative, four-period, two-sequence, crossover study of the comparative pharmacokinetics and bioequivalence of Dzhozafen® (INN: josamycin), film-coated tablets, 500 mg (manufactured by Pharmstandard-Leksredstva OJSC, Russia) and Wilprafen® (INN: josamycin) film-coated tablets, 500 mg (manufactured by Astellas Pharma Europe B. V., Netherlands) in healthy volunteers. (In Russ.)